07 Oct Happiness and Taxpayer Trillions in Corporate Captured Democracy
Table of Contents
The whole pandemic response feels like a succession of profit-chasing backroom deals with the devil, trying to extract the most money for the longest possible time from the taxpayer with the least public scrutiny. Accountability at every level is nil.
Public funded gain of function research messed up, releasing novel coronavirus with scant organized response except months of nepotism money for PPE and billions extra to vaccine pharma repurposing publicly funded mRNA/ad-vector tech and emergency FDA authorization into unprecedented publicly-funded vax campaigns. Excluding prophylaxis, confusing non-medical preventions (masks, healthy lifestyle, vitamin D, zinc etc).
CASE IN POINT: BIG PHARMA – MRNA VACCINES AGAINST SARS-COV2
CASE IN POINT: MOLNUPIRAVIR IVERMECTIN
COVID-19 Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin
Pharmacology Therapeutics PDF at Austin Publishing Group.
There are still many nations where vaccines are not yet widely available,
There is a gradual shift in focus, to antiviral drugs.
Two ways to get new drugs:
- 1. Develop novel antiviral drugs for SARS-CoV-2
- 2. Repurpose existing FDA-approved drugs to treat COVID-19
Ivermectin is the most studied “repurposed” medication globally in randomized clinical trials, retrospective studies and meta-analyses.
Molnupiravir and Ivermectin Anti-SARS-COV-2 Mechanisms, Pharmacokinetics and Pharmacodynamics:
– Molnupiravir is a broad spectrum antiviral agent against SARS-CoV-2, SARS-CoV, seasonal or pandemic influenza and MERS corona virus
– Ivermectin is an FDA-approved, WHO essential drug used as broad spectrum antiparasitic, antibiotic, and which has demonstrated broad spectrum
antiviral activity against RNA viruses, including HIV, Zika, MERS corona virus
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro https://www.sciencedirect.com/science..
5000-fold inhibition of SARS-CoV-2, (99.98% at 48 hours)
The inhibitory concentration IC50 of Molnupiravir shows it to be an even more potent anti-SARS-CoV-2 agent, compared to Ivermectin in vitro.
Both Molnupiravir and ivermectin are well absorbed after oral dosing
Tmax of Molnupiravir being 1-1.75 hours, with a half life of 7 hours
Tmax of ivermectin is 4-6 hours, very long half life of 81-91 hours
Ivermectin, being lipophilic has a large volume of distribution
Ivermectin has the ability to accumulate in the lungs
The anti-SARS-CoV-2 actions, both of
Molnupiravir and ivermectin, are dose and concentration dependent
Molnupiravir active metabolite (NHC-5
Triphosphate), acts as a competitive
alternative substrate for viral RNA
causing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication
There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells
Ivermectin, multifarious actions, binding to SARS-CoV-2 spike protein, reducing cell entry via human ACE2 receptors, reducing viral transcription
– Active treatment of new SARS-CoV-2 infections
– Post-vaccination breakthrough COVID-19 cases
Complimentary pharmacokinetics and
pharmacodynamics of the drugs may be additive or synergistic. This should be further investigated in anti-SARS-CoV-2 antiviral combination therapy e.g. a combination of molnupiravir with Ivermectin putatively, in effects on RdRP or cytokine release.
– The cost for a package of 100 tablets of 3 mg Ivermectin is $2.96 e.g. 12mg per day for 5 days = $0.53
– Cost of Molnupiravir to be negotiated separately with national health services but US govt initial purchase worked out at $700 for the equivalent 5 day course.
CONSEQUENCES OF PROFITABILITY EXPIRATIONS
Patents run out. Drugs become unprofitable. Pharma loses interest in those drugs but, knowing the societal routes to profit, invest in development of analogues that can be released under patent. Profiting from the same service, the same medical results, using a different drug while it is under patent and can be exploited for another 10-25 years easy money. Whatever your opinion of corporate capitalism and profit from medical science, the reality of the current dynamic is a perpetual pressure NOT to develop new better drugs but to simply rebadge old ones once their patents expire.